Sylvester, Richard J.
The use of molecular markers and gene expression profiling provides a promising approach for improving the predictive accuracy of current prognostic indices for predicting which patients with non-muscle-invasive bladder cancer will progress to muscle-invasive disease. There are many statistical pitfalls in establishing the benefit of a multigene expression classifier during its development. First, there are issues related to the identification of the individual genes and the false discovery rate, the instability of the genes identified and their combination into a classifier. Secondly, the classifier should be validated, preferably on an independent data set, to show its reproducibility. Next, it is necessary to show that adding the classifier to an existing model based on the most important clinical and pathological factors improves the predictive accuracy of the model. This cannot be determined based on the classifier's hazard ratio or p-value in a multivariate model, but should be assessed based on an improvement in statistics such as the area under the curve and the concordance index. Finally, nomograms are superior to stage and risk group classifications for predicting outcome, but the model predicting the outcome must be well calibrated. It is important for investigators to be aware of these pitfalls in order to develop statistically valid classifiers that will truly improve our ability to predict a patient's risk of progression.
- Sylvester RJ, TSW Urology, 1, 15 (2006)
- Sylvester Richard J., van der Meijden Adrian P.M., Oosterlinck Willem, Witjes J. Alfred, Bouffioux Christian, Denis Louis, Newling Donald W.W., Kurth Karlheinz, Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials, 10.1016/j.eururo.2005.12.031
- Schrier Barthold Ph., Hollander Maarten P., van Rhijn Bas W.G., Kiemeney Lambertus A.L.M., Alfred Witjes J., Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and Progressive Tumours and Implications for Therapy, 10.1016/j.eururo.2003.10.006
- Habuchi Tomonori, Marberger Michael, Droller Michael J., Hemstreet George P., Grossman H. Barton, Schalken Jack A., Schmitz-Dräger Bernd J., Murphy William M., Bono Aldo V., Goebell Peter, Getzenberg Robert H., Hautmann Stefan H., Messing Edward, Fradet Yves, Lokeshwar Vinata B., Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers, 10.1016/j.urology.2005.08.065
- Bensalah Karim, Montorsi Francesco, Shariat Shahrokh F., Challenges of Cancer Biomarker Profiling, 10.1016/j.eururo.2007.09.036
- Simon Richard, Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers, 10.1200/jco.2005.02.8712
- Michiels S, Koscielny S, Hill C, Interpretation of microarray data in cancer, 10.1038/sj.bjc.6603673
- Pawitan Y., Michiels S., Koscielny S., Gusnanto A., Ploner A., False discovery rate, sensitivity and sample size for microarray studies, 10.1093/bioinformatics/bti448
- Pawitan Y., Murthy K. R. K., Michiels S., Ploner A., Bias in the estimation of false discovery rate in microarray studies, 10.1093/bioinformatics/bti626
- Michiels Stefan, Koscielny Serge, Hill Catherine, Prediction of cancer outcome with microarrays: a multiple random validation strategy, 10.1016/s0140-6736(05)17866-0
- Dudoit Sandrine, Fridlyand Jane, Speed Terence P, Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data, 10.1198/016214502753479248
- McShane Lisa M., Altman Douglas G., Sauerbrei Willi, Taube Sheila E., Gion Massimo, Clark Gary M., REporting recommendations for tumour MARKer prognostic studies (REMARK), 10.1016/j.ejca.2005.03.032
- Altman Douglas G., Royston Patrick, What do we mean by validating a prognostic model?, 10.1002/(sici)1097-0258(20000229)19:4<453::aid-sim350>3.0.co;2-5
- Molinaro A. M., Simon R., Pfeiffer R. M., Prediction error estimation: a comparison of resampling methods, 10.1093/bioinformatics/bti499
- Kyzas Panayiotis A., Denaxa-Kyza Despina, Ioannidis John P.A., Almost all articles on cancer prognostic markers report statistically significant results, 10.1016/j.ejca.2007.08.030
- Kattan M. W., Judging New Markers by Their Ability to Improve Predictive Accuracy, 10.1093/jnci/95.9.634
- Pepe M. S., Limitations of the Odds Ratio in Gauging the Performance of a Diagnostic, Prognostic, or Screening Marker, 10.1093/aje/kwh101
- Kattan M. W., Evaluating a New Marker's Predictive Contribution, 10.1158/1078-0432.ccr-03-0061
- Dunkler Daniela, Michiels Stefan, Schemper Michael, Gene expression profiling: Does it add predictive accuracy to clinical characteristics in cancer prognosis?, 10.1016/j.ejca.2006.11.018
- SCHEMPER MICHAEL, STARE JANEZ, EXPLAINED VARIATION IN SURVIVAL ANALYSIS, 10.1002/(sici)1097-0258(19961015)15:19<1999::aid-sim353>3.0.co;2-d
- Schemper Michael, Henderson Robin, Predictive Accuracy and Explained Variation in Cox Regression, 10.1111/j.0006-341x.2000.00249.x
- Schemper Michael, Predictive accuracy and explained variation, 10.1002/sim.1486
- KATTAN MICHAEL W., Comparison of Cox Regression With Other Methods for Determining Prediction Models and Nomograms, 10.1097/01.ju.0000094764.56269.2d
- Pintilie Melania, Competing Risks, ISBN:9780470870709, 10.1002/9780470870709
- HARRELL FRANK E., LEE KERRY L., MARK DANIEL B., MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS, 10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
- Heagerty Patrick J., Zheng Yingye, Survival Model Predictive Accuracy and ROC Curves, 10.1111/j.0006-341x.2005.030814.x
- Kattan Michael W., Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer : , 10.1097/00042307-200303000-00005
- Shariat Shahrokh F., Margulis Vitaly, Lotan Yair, Montorsi Francesco, Karakiewicz Pierre I., Nomograms for Bladder Cancer, 10.1016/j.eururo.2008.01.004
- SHARIAT S, ZIPPE C, LUDECKE G, BOMAN H, SANCHEZCARBAYO M, CASELLA R, MIAN C, FRIEDRICH M, EISSA S, AKAZA H, NOMOGRAMS INCLUDING NUCLEAR MATRIX PROTEIN 22 FOR PREDICTION OF DISEASE RECURRENCE AND PROGRESSION IN PATIENTS WITH Ta, T1 OR CIS TRANSITIONAL CELL CARCINOMA OF THE BLADDER, 10.1097/01.ju.0000154696.48217.75
- Karakiewicz Pierre I., Shariat Shahrokh F., Palapattu Ganesh S., Perrotte Paul, Lotan Yair, Rogers Craig G., Amiel Gilad E., Vazina Amnon, Gupta Amit, Bastian Patrick J., Sagalowsky Arthur I., Schoenberg Mark, Lerner Seth P., Precystectomy Nomogram for Prediction of Advanced Bladder Cancer Stage, 10.1016/j.eururo.2006.06.010
- Postoperative Nomogram Predicting Risk of Recurrence After Radical Cystectomy for Bladder Cancer, 10.1200/jco.2005.05.3884
- Karakiewicz Pierre I., Shariat Shahrokh F., Palapattu Ganesh S., Gilad Amiel E., Lotan Yair, Rogers Craig G., Vazina Amnon, Gupta Amit, Bastian Patrick J., Perrotte Paul, Sagalowsky Arthur I., Schoenberg Mark, Lerner Seth P., Nomogram for Predicting Disease Recurrence After Radical Cystectomy for Transitional Cell Carcinoma of the Bladder, 10.1016/j.juro.2006.06.025
- Shariat S. F., Karakiewicz P. I., Palapattu G. S., Amiel G. E., Lotan Y., Rogers C. G., Vazina A., Bastian P. J., Gupta A., Sagalowsky A. I., Schoenberg M., Lerner S. P., Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy, 10.1158/1078-0432.ccr-06-0372
- Shariat Shahrokh F., Karakiewicz Pierre I., Ashfaq Raheela, Lerner Seth P., Palapattu Ganesh S., Cote Richard J., Sagalowsky Arthur I., Lotan Yair, Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy, 10.1002/cncr.23162
- Pencina Michael J., D' Agostino Ralph B., D' Agostino Ralph B., Vasan Ramachandran S., Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond, 10.1002/sim.2929
Bibliographic reference |
Sylvester, Richard J.. Combining a molecular profile with a clinical and pathological profile: Biostatistical considerations. In: Scandinavian Journal of Urology and Nephrology, Vol. 42, p. 185-190 (2008) |
Permanent URL |
http://hdl.handle.net/2078.1/36227 |